A Phase Ib, Multicentre, Double Blind, Randomized, Two-part Study, First Part Multiple Rising Dose and Second Part Two-way Cross-over, to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of BI 443651 Compared to Placebo Via Respimat® in Healthy Volunteers and CF Subjects.
Phase of Trial: Phase I
Latest Information Update: 15 Jul 2017
At a glance
- Drugs BI 443651 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 11 Jul 2017 Planned End Date changed from 1 Nov 2017 to 30 Dec 2017.
- 11 Jul 2017 Planned primary completion date changed from 1 Nov 2017 to 30 Dec 2017.
- 12 Jun 2017 Planned number of patients changed from 136 to 64.